Summary
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
According to APO Research, The global Benign Prostatic Hyperplasia (BPH) Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Benign Prostatic Hyperplasia (BPH) Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Benign Prostatic Hyperplasia (BPH) Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Benign Prostatic Hyperplasia (BPH) Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Benign Prostatic Hyperplasia (BPH) Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA and Mylan, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Benign Prostatic Hyperplasia (BPH) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Benign Prostatic Hyperplasia (BPH) Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Benign Prostatic Hyperplasia (BPH) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Benign Prostatic Hyperplasia (BPH) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Benign Prostatic Hyperplasia (BPH) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Benign Prostatic Hyperplasia (BPH) Drugs sales, projected growth trends, production technology, application and end-user industry.
Benign Prostatic Hyperplasia (BPH) Drugs segment by Company
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
Benign Prostatic Hyperplasia (BPH) Drugs segment by Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Benign Prostatic Hyperplasia (BPH) Drugs segment by Application
Hospitals
Drugstores
Others
Benign Prostatic Hyperplasia (BPH) Drugs segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Benign Prostatic Hyperplasia (BPH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Benign Prostatic Hyperplasia (BPH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Benign Prostatic Hyperplasia (BPH) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Benign Prostatic Hyperplasia (BPH) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Benign Prostatic Hyperplasia (BPH) Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 Benign Prostatic Hyperplasia (BPH) Drugs Market by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Benign Prostatic Hyperplasia (BPH) Drugs Market by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics
2.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Drivers
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Industry Opportunities and Challenges
2.4 Benign Prostatic Hyperplasia (BPH) Drugs Industry Restraints
3 Global Market Growth Prospects
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Estimates and Forecasts (2019-2030)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2019 VS 2023 VS 2030
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2019-2024)
3.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2025-2030)
3.2.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2019-2030)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Estimates and Forecasts 2019-2030
3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
3.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2019 VS 2023 VS 2030
3.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2019-2024)
3.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2025-2030)
3.4.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2019-2030)
3.5 US & Canada
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 Middle East, Africa and Latin America
4 Market Competitive Landscape by Manufacturers
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2019-2024)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2019-2024)
4.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2023
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2019-2024)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2019-2024)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Sales Share Top 10 and Top 5 in 2023
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Manufacturers (2019-2024)
4.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Key Manufacturers Ranking, 2022 VS 2023 VS 2024
4.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers, Product Type & Application
4.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Commercialization Time
4.8 Market Competitive Analysis
4.8.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market CR5 and HHI
4.8.2 2023 Benign Prostatic Hyperplasia (BPH) Drugs Tier 1, Tier 2, and Tier 3
5 Benign Prostatic Hyperplasia (BPH) Drugs Market by Type
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type
5.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019 VS 2023 VS 2030)
5.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2030) & (US$ Million)
5.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2030)
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019 VS 2023 VS 2030)
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2030) & (M Units)
5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2030)
5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type
6 Benign Prostatic Hyperplasia (BPH) Drugs Market by Application
6.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application
6.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019 VS 2023 VS 2030)
6.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2030) & (US$ Million)
6.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2030)
6.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
6.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019 VS 2023 VS 2030)
6.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2030) & (M Units)
6.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2030)
6.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application
7 Company Profiles
7.1 Eli Lilly
7.1.1 Eli Lilly Comapny Information
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
7.1.5 Eli Lilly Recent Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Comapny Information
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
7.2.5 GlaxoSmithKline Recent Developments
7.3 Astellas Pharma
7.3.1 Astellas Pharma Comapny Information
7.3.2 Astellas Pharma Business Overview
7.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
7.3.5 Astellas Pharma Recent Developments
7.4 Sanofi
7.4.1 Sanofi Comapny Information
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
7.4.5 Sanofi Recent Developments
7.5 Pfizer
7.5.1 Pfizer Comapny Information
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
7.5.5 Pfizer Recent Developments
7.6 Abbott
7.6.1 Abbott Comapny Information
7.6.2 Abbott Business Overview
7.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
7.6.5 Abbott Recent Developments
7.7 Allergan
7.7.1 Allergan Comapny Information
7.7.2 Allergan Business Overview
7.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
7.7.5 Allergan Recent Developments
7.8 TEVA
7.8.1 TEVA Comapny Information
7.8.2 TEVA Business Overview
7.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
7.8.5 TEVA Recent Developments
7.9 Mylan
7.9.1 Mylan Comapny Information
7.9.2 Mylan Business Overview
7.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
7.9.5 Mylan Recent Developments
7.10 Novartis
7.10.1 Novartis Comapny Information
7.10.2 Novartis Business Overview
7.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
7.10.5 Novartis Recent Developments
7.11 Merck
7.11.1 Merck Comapny Information
7.11.2 Merck Business Overview
7.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
7.11.5 Merck Recent Developments
8 North America
8.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
8.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2030)
8.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2030)
8.1.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2019-2030)
8.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
8.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2030)
8.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2030)
8.2.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2019-2030)
8.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
8.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
8.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019 VS 2023 VS 2030)
8.3.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Price by Country (2019-2030)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
9.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2030)
9.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2030)
9.1.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2019-2030)
9.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
9.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2030)
9.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2030)
9.2.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2019-2030)
9.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
9.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
9.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019 VS 2023 VS 2030)
9.3.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Price by Country (2019-2030)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
10 China
10.1 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
10.1.1 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2030)
10.1.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2030)
10.1.3 China Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2019-2030)
10.2 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
10.2.1 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2030)
10.2.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2030)
10.2.3 China Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
11.1.1 Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2030)
11.1.2 Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2030)
11.1.3 Asia Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2019-2030)
11.2 Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
11.2.1 Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2030)
11.2.2 Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2030)
11.2.3 Asia Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2019-2030)
11.3 Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
11.3.1 Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
11.3.2 Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019 VS 2023 VS 2030)
11.3.3 Asia Benign Prostatic Hyperplasia (BPH) Drugs Price by Country (2019-2030)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 China Taiwan
11.3.9 Southeast Asia
12 Middle East, Africa and Latin America
12.1 MEALA Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
12.1.1 MEALA Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2030)
12.1.2 MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2030)
12.1.3 MEALA Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2019-2030)
12.2 MEALA Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
12.2.1 MEALA Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2030)
12.2.2 MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2030)
12.2.3 MEALA Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2019-2030)
12.3 MEALA Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
12.3.1 MEALA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
12.3.2 MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019 VS 2023 VS 2030)
12.3.3 MEALA Benign Prostatic Hyperplasia (BPH) Drugs Price by Country (2019-2030)
12.3.4 Mexico
12.3.5 Brazil
12.3.6 Israel
12.3.7 Argentina
12.3.8 Colombia
12.3.9 Turkey
12.3.10 Saudi Arabia
12.3.11 UAE
13 Value Chain and Sales Channels Analysis
13.1 Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Analysis
13.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process
13.2 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
13.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Alpha-Blocker Major Manufacturers
Table 3. Phosphodiesterase Type-5 Inhibitors Major Manufacturers
Table 4. Others Major Manufacturers
Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 6. Hospitals Major Manufacturers
Table 7. Drugstores Major Manufacturers
Table 8. Others Major Manufacturers
Table 9. Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
Table 10. Benign Prostatic Hyperplasia (BPH) Drugs Industry Drivers
Table 11. Benign Prostatic Hyperplasia (BPH) Drugs Industry Opportunities and Challenges
Table 12. Benign Prostatic Hyperplasia (BPH) Drugs Industry Restraints
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2019-2024)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2025-2030)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (M Units)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2019-2024) & (M Units)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2025-2030) & (M Units)
Table 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2019-2024)
Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2025-2030)
Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (US$ Million) & (2019-2024)
Table 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2019-2024)
Table 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (US$ Million) & (2019-2024)
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2019-2024)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Price (US$/Unit) of Manufacturers (2019-2024)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Key Manufacturers Ranking, 2022 VS 2023 VS 2024
Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Key Manufacturers Manufacturing Sites & Headquarters
Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers, Product Type & Application
Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Commercialization Time
Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030) & (US$ Million)
Table 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2024)
Table 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2025-2030)
Table 39. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type 2019 VS 2023 VS 2030 (M Units)
Table 40. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)
Table 41. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030) & (M Units)
Table 42. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2024)
Table 43. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2025-2030)
Table 44. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2019-2024) & (US$/Unit)
Table 45. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2025-2030) & (US$/Unit)
Table 46. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 47. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024) & (US$ Million)
Table 48. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030) & (US$ Million)
Table 49. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2024)
Table 50. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2025-2030)
Table 51. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application 2019 VS 2023 VS 2030 (M Units)
Table 52. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)
Table 53. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030) & (M Units)
Table 54. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2024)
Table 55. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2025-2030)
Table 56. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2019-2024) & (US$/Unit)
Table 57. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2025-2030) & (US$/Unit)
Table 58. Eli Lilly Company Information
Table 59. Eli Lilly Business Overview
Table 60. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 61. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
Table 62. Eli Lilly Recent Development
Table 63. GlaxoSmithKline Company Information
Table 64. GlaxoSmithKline Business Overview
Table 65. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 66. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
Table 67. GlaxoSmithKline Recent Development
Table 68. Astellas Pharma Company Information
Table 69. Astellas Pharma Business Overview
Table 70. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 71. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
Table 72. Astellas Pharma Recent Development
Table 73. Sanofi Company Information
Table 74. Sanofi Business Overview
Table 75. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 76. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
Table 77. Sanofi Recent Development
Table 78. Pfizer Company Information
Table 79. Pfizer Business Overview
Table 80. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 81. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
Table 82. Pfizer Recent Development
Table 83. Abbott Company Information
Table 84. Abbott Business Overview
Table 85. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 86. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
Table 87. Abbott Recent Development
Table 88. Allergan Company Information
Table 89. Allergan Business Overview
Table 90. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 91. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
Table 92. Allergan Recent Development
Table 93. TEVA Company Information
Table 94. TEVA Business Overview
Table 95. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 96. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
Table 97. TEVA Recent Development
Table 98. Mylan Company Information
Table 99. Mylan Business Overview
Table 100. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 101. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
Table 102. Mylan Recent Development
Table 103. Novartis Company Information
Table 104. Novartis Business Overview
Table 105. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 106. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
Table 107. Novartis Recent Development
Table 108. Merck Company Information
Table 109. Merck Business Overview
Table 110. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 111. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
Table 112. Merck Recent Development
Table 113. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 114. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030) & (US$ Million)
Table 115. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)
Table 116. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030) & (M Units)
Table 117. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2019-2024) & (US$/Unit)
Table 118. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2025-2030) & (US$/Unit)
Table 119. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024) & (US$ Million)
Table 120. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030) & (US$ Million)
Table 121. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)
Table 122. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030) & (M Units)
Table 123. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2019-2024) & (US$/Unit)
Table 124. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2025-2030) & (US$/Unit)
Table 125. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 126. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 127. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 128. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019 VS 2023 VS 2030) & (M Units)
Table 129. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)
Table 130. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)
Table 131. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2019-2024) & (US$/Unit)
Table 132. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2025-2030) & (US$/Unit)
Table 133. US Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 134. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 135. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 136. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030) & (US$ Million)
Table 137. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)
Table 138. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030) & (M Units)
Table 139. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2019-2024) & (US$/Unit)
Table 140. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2025-2030) & (US$/Unit)
Table 141. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024) & (US$ Million)
Table 142. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030) & (US$ Million)
Table 143. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)
Table 144. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030) & (M Units)
Table 145. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2019-2024) & (US$/Unit)
Table 146. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2025-2030) & (US$/Unit)
Table 147. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 148. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 149. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 150. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019 VS 2023 VS 2030) & (M Units)
Table 151. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)
Table 152. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)
Table 153. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2019-2024) & (US$/Unit)
Table 154. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2025-2030) & (US$/Unit)
Table 155. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 156. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 157. Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 158. Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 159. Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 160. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 161. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030) & (US$ Million)
Table 162. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)
Table 163. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030) & (M Units)
Table 164. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2019-2024) & (US$/Unit)
Table 165. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2025-2030) & (US$/Unit)
Table 166. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024) & (US$ Million)
Table 167. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030) & (US$ Million)
Table 168. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)
Table 169. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030) & (M Units)
Table 170. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2019-2024) & (US$/Unit)
Table 171. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2025-2030) & (US$/Unit)
Table 172. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 173. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030) & (US$ Million)
Table 174. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)
Table 175. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030) & (M Units)
Table 176. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2019-2024) & (US$/Unit)
Table 177. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2025-2030) & (US$/Unit)
Table 178. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024) & (US$ Million)
Table 179. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030) & (US$ Million)
Table 180. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)
Table 181. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030) & (M Units)
Table 182. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2019-2024) & (US$/Unit)
Table 183. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2025-2030) & (US$/Unit)
Table 184. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 185. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 186. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 187. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019 VS 2023 VS 2030) & (M Units)
Table 188. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)
Table 189. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)
Table 190. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2019-2024) & (US$/Unit)
Table 191. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2025-2030) & (US$/Unit)
Table 192. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 193. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 194. Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 195. Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 196. Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 197. Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 198. Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 199. Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 200. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 201. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030) & (US$ Million)
Table 202. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)
Table 203. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030) & (M Units)
Table 204. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2019-2024) & (US$/Unit)
Table 205. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Type (2025-2030) & (US$/Unit)
Table 206. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024) & (US$ Million)
Table 207. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030) & (US$ Million)
Table 208. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)
Table 209. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030) & (M Units)
Table 210. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2019-2024) & (US$/Unit)
Table 211. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Application (2025-2030) & (US$/Unit)
Table 212. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 213. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 214. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 215. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019 VS 2023 VS 2030) & (M Units)
Table 216. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)
Table 217. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)
Table 218. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2019-2024) & (US$/Unit)
Table 219. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Country (2025-2030) & (US$/Unit)
Table 220. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 221. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 222. Israel Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 223. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 224. Colombia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 225. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 226. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 227. UAE Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Table 228. Key Raw Materials
Table 229. Raw Materials Key Suppliers
Table 230. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 231. Benign Prostatic Hyperplasia (BPH) Drugs Customers List
Table 232. Research Programs/Design for This Report
Table 233. Authors List of This Report
Table 234. Secondary Sources
Table 235. Primary Sources
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Share 2019 VS 2023 VS 2030
Figure 4. Alpha-Blocker Picture
Figure 5. Phosphodiesterase Type-5 Inhibitors Picture
Figure 6. Others Picture
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Share 2019 VS 2023 VS 2030
Figure 9. Hospitals Picture
Figure 10. Drugstores Picture
Figure 11. Others Picture
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region: 2023 Versus 2030
Figure 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2019-2030)
Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (2019-2030) & (M Units)
Figure 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (CAGR) by Region: 2019 VS 2023 VS 2030 (M Units)
Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2019-2030)
Figure 20. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2019-2030) & (M Units)
Figure 21. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2019-2030) & (M Units)
Figure 22. China Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2019-2030) & (M Units)
Figure 23. Asia (Excluding China) Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2019-2030) & (M Units)
Figure 24. Middle East, Africa and Latin America (Excluding China) Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2019-2030) & (M Units)
Figure 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2023
Figure 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Sales Share Top 10 and Top 5 in 2023
Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type 2019 VS 2023 VS 2030
Figure 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2030)
Figure 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019 VS 2023 VS 2030) & (M Units)
Figure 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type 2019 VS 2023 VS 2030
Figure 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2030)
Figure 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application 2019 VS 2023 VS 2030
Figure 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2030)
Figure 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019 VS 2023 VS 2030) & (M Units)
Figure 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application 2019 VS 2023 VS 2030
Figure 39. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2030)
Figure 40. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2019-2030)
Figure 41. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2019-2030)
Figure 42. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2019-2030)
Figure 43. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2019-2030)
Figure 44. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country (2019-2030)
Figure 45. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country (2019-2030)
Figure 46. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2019-2030)
Figure 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2019-2030)
Figure 48. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2019-2030)
Figure 49. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2019-2030)
Figure 50. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country (2019-2030)
Figure 51. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country (2019-2030)
Figure 52. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2019-2030)
Figure 53. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2019-2030)
Figure 54. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2019-2030)
Figure 55. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2019-2030)
Figure 56. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2019-2030)
Figure 57. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2019-2030)
Figure 58. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2019-2030)
Figure 59. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2019-2030)
Figure 60. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country (2019-2030)
Figure 61. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country (2019-2030)
Figure 62. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2019-2030)
Figure 63. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2019-2030)
Figure 64. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2019-2030)
Figure 65. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2019-2030)
Figure 66. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country (2019-2030)
Figure 67. MEALA Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country (2019-2030)
Figure 68. Benign Prostatic Hyperplasia (BPH) Drugs Value Chain
Figure 69. Manufacturing Cost Structure
Figure 70. Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process
Figure 71. Direct Comparison with Distribution Share
Figure 72. Distributors Profiles
Figure 73. Years Considered
Figure 74. Research Process
Figure 75. Key Executives Interviewed
